INS and Hypoglycemia: While transitioning from insulin to GLP-1/GIP receptor agonists (e.g., tirzepatide, semaglutide, dulaglutide) offers benefits such as improved glycemic control, weight loss, and reduced hypoglycemia risk, some complications can arise during the switch, as shown in Table 3.